



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Navicixizumab

Cat. No.:	HY-P99377
CAS No.:	1638338-43-8
Target:	Notch
Pathway:	Neuronal Signaling; Stem Cell/Wnt
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer ^{[1][2][3]} .
IC₅₀ & Target	IC50: hVEGF (0.36 nM), mVEGF (25.5 nM), hDLL4 (1.3 nM)
In Vitro	Navicixizumab (0-100 μM) reduces proliferation of human endothelial cells in the presence of hVEGF ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Navicixizumab (15 mg/kg, once a week for 4 weeks) inhibits colon xenograft tumor growth ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Fu S, et al. Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. *J Clin Oncol*. 2022 Aug 10;40(23):2568-2577.
- [2]. Perez-Fidalgo JA, et al. NOTCH signalling in ovarian cancer angiogenesis. *Ann Transl Med*. 2020 Dec;8(24):1705.
- [3]. Wan-Ching Yen, et al. Abstract C164: Dual targeting of the DLL4 and VEGF pathways with a bispecific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency. *Mol Cancer Ther* (2015) 14 (12_Supplement_2): C164.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA